Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143

BACKGROUND: Immunotherapies have demonstrated efficacy across a diverse set of tumors supporting further evaluation in glioblastoma. The objective of this study was to evaluate the safety/tolerability and describe immune-mediated effects of nivolumab ± ipilimumab in patients with recurrent glioblast...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Neuro Oncol
Hlavní autoři: Omuro, Antonio, Vlahovic, Gordana, Lim, Michael, Sahebjam, Solmaz, Baehring, Joachim, Cloughesy, Timothy, Voloschin, Alfredo, Ramkissoon, Shakti H, Ligon, Keith L, Latek, Robert, Zwirtes, Ricardo, Strauss, Lewis, Paliwal, Prashni, Harbison, Christopher T, Reardon, David A, Sampson, John H
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2018
Témata:
Clinical Investigations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5892140/
https://ncbi.nlm.nih.gov/pubmed/29106665
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox208
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky